INMB logo

INMBINmune Bio Inc

$1.30
$0.02
(1.56%)
Pre-Market
Updated: 05:58 AM EDT·Prev Close $1.28
EarningsAug 6
Mkt Cap$34.03M
Vol75.00
News
all
press releases
INmune Bio (INMB) Q4 2025 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...
PR Newswire
News Placeholder
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial?
The FDA meeting minutes suggest INmune Bio’s late-stage Alzheimer’s trial design is on track.
Stocktwits
News Placeholder
INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised INmune Bio from a "sell" rating to a "hold" rating in a research note on Sunday...
MarketBeat
News Placeholder
Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. $INMB
Praetorian PR LLC lowered its stake in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 99.3% in the second quarter, according to the company in its most recent disclosure with the Securities and...
MarketBeat
News Placeholder
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
News Placeholder
INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
News Placeholder
INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss
Investing.com -- INmune Bio (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its investment case.
investing.com
News Placeholder
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial
The primary endpoint of the study was not met in the intent-to-treat population, the company said.
Stocktwits
News Placeholder
INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results
Investing.com -- INmune Bio Inc. (NASDAQ:INMB) stock fell 60% in pre-market trading Monday after the company reported mixed results from its Phase 2 MINDFuL trial of XPro in early Alzheimer’s disease patients.
investing.com
<
1
2
...
>

Advertisement|Remove ads.